Gene Therapy in Amyotrophic Lateral Sclerosis.

However, since participant numbers were low in the initial trial, BIIB067 was extended to a phase 3 clinical trial; however, the primary outcomes of measuring disease progression in ALS fast progressors at 28 weeks of treatment did not reach statistical significance [ 36 ].

also in 111,027 other papers